Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.

Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.

Abstract: Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.

Abstract: A method for quantification of a titer of a neutralizing antibody to a neurotoxin is disclosed. The method comprises the steps: (a) mixing a standard sample containing a fixed amount of a neurotoxin and a test sample containing a neutralizing antibody to said neurotoxin; (b) administering the mixture obtained in step (a) into the muscle of a non-human mammal; (c) applying electric stimulus to said non-human mammal; (d) measuring a compound muscle action potential (CMAP) due to contraction of the muscle of said mammal by application of electric stimulus with an electromyograph; and (e) analyzing CMAP amplitude data obtained in step (d) for an extent of decrease in amplitude by a non-neutralized neurotoxin to thereby quantify a titer of the neutralizing antibody contained in the test sample.

Abstract: A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.

Abstract: Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.

Abstract: An M toxin of type A botulinum toxin (HA-negative substance) and a mixture of L toxin and LL toxin (HA-positive substance) are compared and examined in inhibitory action for neuromuscular transmission and therapeutic index. As a result, it is found that M toxin of type A botulinum toxin has characteristics of: 1) having an excellent inhibitory action for neuromuscular transmission; 2)showing a high therapeutic index; 3) showing a low antigenicity and 4) suffering from little reduction in efficacy even after repeatedly administered, compared with the mixture of L toxin and LL toxin.

Abstract: A remedy for muscle hyperactivity, comprising a purified botulinum neurotoxin as an active ingredient.

Abstract: The present invention provides a method for producing a material dispersed with ultraviolet shielding fine particles, characterized by subjecting a starting material liquid mixture comprising particles comprising one or more inorganic substances having shielding abilities against ultraviolet light, one or more silicone dispersants selected from modified silicones and reactive silicones, and a silicone oil to a mill treatment and/or a high-pressure dispersion treatment; and ultraviolet shielding fine particles or a material dispersed therewith, characterized by being produced by the above method. Also, the present invention provides a method of producing a powdery product of ultraviolet shielding fine particles, characterized by drying the material dispersed with ultraviolet shielding fine particles obtainable by the above method.

Abstract: Ultraviolet shielding composite fine particles having transparency in a visible light region, comprising matrix particles comprising an aggregate of primary particles having an average particle size of from 0.001 to 0.3 .mu.m, the aggregate being formed while the primary particles retain their shapes; and daughter particles having an average particle size of from 0.001 to 0.1 .mu.m, the daughter particles being dispersed in and supported by the matrix particles, wherein the daughter particles have a smaller band gap energy than the particles constituting the matrix particles and are capable of absorbing ultraviolet light, and wherein the surfaces of the composite fine particles are coated with one or more silicones selected from the group consisting of modified silicones, reactive silicones, and silicone-modified copolymers, and wherein the ultraviolet shielding composite fine particles have substantially no catalytic activities.

Abstract: The present invention is directed to ultraviolet shielding composite fine particles having transparency in a visible light region include (a) matrix particles comprising an aggregate of primary particles having an average particle diameter of from 0.001 to 0.3 .mu.m, the aggregate being formed while the primary particles retain their shapes; and (b) daughter particles having an average particle diameter of from 0.001 to 0.1 .mu.m, the daughter particles being dispersed in and supported by the matrix particles. In the composite fine particles, the daughter particles have a smaller band gap energy than the particles constituting the matrix particles and are capable of absorbing ultraviolet light, and the resulting ultraviolet shielding composite fine particles have substantially no catalytic activity.

Abstract: The present invention is directed to ultraviolet shielding composite fine particles having transparency in a visible light region, comprising (a) matrix particles comprising an aggregate of primary particles having an average particles diameter of from 0.001 to 0.3 .mu.m, said aggregate being formed while retaining the shapes of the primary particles; and (b) daughter particles having an average particle diameter of from 0.001 to 0.1 .mu.m, said daughter particles being dispersed in and supported by said matrix particles, wherein said daughter particles have a smaller band gap energy than that of particles constituting said matrix particles, and possess capability of absorbing ultraviolet light. The composite fine particles are produced by preparing a liquid mixture containing a mixture comprising starting materials for matrix particles and for daughter particles; forming droplets from the liquid mixture; and drying the formed droplets and/or pyrolyzing starting materials for pyrolysis therein.